Profile data is unavailable for this security.
About the company
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
- Revenue in INR (TTM)11.23bn
- Net income in INR-6.71m
- Incorporated1987
- Employees1.03k
- LocationShilpa Medicare LtdShilpa House#12-6-214/A1,, Hyderabad Road,RAICHUR 584135IndiaIND
- Phone+91 8 532238704
- Fax+91 8 532238876
- Websitehttps://www.vbshilpa.com/
More ▼
Mergers & acquisitions
| Acquired company | SHILPAMED:NSI since announced | Transaction value |
|---|---|---|
| Pilnova Pharma Inc | 50.48% | -- |
Data delayed at least 15 minutes, as of Apr 25 2024 11:02 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Ltd | 17.96bn | 1.02bn | 30.33bn | 6.10k | 30.11 | -- | 16.47 | 1.69 | 10.93 | 10.93 | 192.26 | -- | -- | -- | -- | 2,943,454.00 | -- | 6.07 | -- | 8.90 | 69.39 | 65.35 | 5.61 | 6.30 | -- | 5.11 | -- | 14.79 | 8.30 | 9.81 | -8.11 | 28.15 | 8.25 | 17.61 |
| SeQuent Scientific Ltd | 13.75bn | -1.29bn | 31.40bn | 478.00 | -- | -- | -- | 2.28 | -5.18 | -5.18 | 55.33 | -- | -- | -- | -- | 28,769,920.00 | -- | 2.33 | -- | 3.67 | 42.78 | 42.47 | -8.97 | 2.59 | -- | -0.3894 | -- | 17.27 | 0.5728 | 10.84 | -395.83 | -- | 12.88 | -- |
| Gufic BioSciences Ltd | 7.85bn | 841.95m | 31.53bn | 1.63k | 36.47 | -- | 29.89 | 4.02 | 8.62 | 8.62 | 80.38 | -- | -- | -- | -- | 4,820,074.00 | -- | 12.30 | -- | 23.08 | 51.08 | 44.91 | 10.73 | 9.84 | -- | 8.22 | -- | 1.39 | -11.36 | 17.47 | -16.84 | 37.06 | 86.82 | 14.87 |
| Supriya Lifescience Ltd | 5.54bn | 1.20bn | 32.38bn | 392.00 | 26.87 | -- | 23.93 | 5.84 | 14.97 | 14.97 | 68.93 | -- | -- | -- | -- | 14,144,410.00 | -- | 20.77 | -- | 29.06 | 61.94 | 55.83 | 21.72 | 24.33 | -- | 63.63 | -- | 2.02 | -13.04 | 16.70 | -40.81 | 59.41 | 85.55 | -- |
| Dishman Carbogen Amcis Ltd | 25.80bn | -1.54bn | 36.60bn | 1.30k | -- | -- | 24.84 | 1.42 | -9.84 | -9.84 | 164.35 | -- | -- | -- | -- | 19,919,850.00 | -- | 0.4699 | -- | 0.5665 | 76.93 | 74.36 | -5.98 | 1.82 | -- | -0.1245 | -- | 202.76 | 12.72 | 7.32 | -265.46 | -- | 21.54 | -- |
| Hikal Ltd | 18.16bn | 716.22m | 38.43bn | 2.14k | 53.70 | -- | 20.92 | 2.12 | 5.80 | 5.80 | 147.17 | -- | -- | -- | -- | 8,477,077.00 | -- | 5.86 | -- | 8.87 | 52.08 | 45.41 | 3.94 | 6.37 | -- | 2.78 | -- | 10.14 | 4.13 | 9.25 | -51.16 | 0.2973 | 23.35 | 4.42 |
| Unichem Laboratories Ltd | 16.75bn | 145.69m | 41.64bn | 3.12k | 286.23 | -- | 31.95 | 2.49 | 2.07 | 2.07 | 234.69 | -- | -- | -- | -- | 5,364,373.00 | -- | -1.38 | -- | -1.66 | 59.94 | 56.15 | 0.8696 | -3.60 | -- | -0.9613 | -- | -- | 5.76 | 10.51 | -711.67 | -- | -22.60 | -- |
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 43.10bn | 338.00 | 31.39 | -- | 24.83 | 7.13 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Drugs Ltd | 26.51bn | 1.80bn | 46.04bn | 1.50k | 25.65 | -- | 19.94 | 1.74 | 19.52 | 19.52 | 287.30 | -- | -- | -- | -- | 17,673,360.00 | -- | 9.91 | -- | 16.40 | 32.25 | 22.33 | 6.81 | 8.23 | -- | 8.29 | -- | 5.53 | 9.14 | 16.56 | -18.89 | 15.11 | 17.20 | 31.95 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 47.09bn | 1.40k | 24.20 | -- | 17.80 | 2.57 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 51.94bn | 1.03k | -- | -- | 48.84 | 4.62 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 54.02bn | 838.00 | 37.37 | -- | 33.98 | 6.65 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 66.15bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| F D C Ltd | 19.16bn | 2.90bn | 73.70bn | 6.37k | 25.68 | -- | 22.42 | 3.85 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 76.20bn | 1.40k | 23.86 | -- | 19.68 | 3.62 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
Data as of Apr 25 2024. Currency figures normalised to Shilpa Medicare Ltd's reporting currency: Indian Rupee INR
2.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 1.25m | 1.44% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 383.83k | 0.44% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 192.44k | 0.22% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 65.49k | 0.08% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 40.05k | 0.05% |
| ITI Asset Management Ltd. (India)as of 31 Mar 2024 | 36.80k | 0.04% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 27.25k | 0.03% |
| DFA Australia Ltd.as of 29 Feb 2024 | 6.79k | 0.01% |
| Groww Asset Management Ltd.as of 31 Mar 2024 | 291.00 | 0.00% |
| Lacuna Verm�gen GmbHas of 30 Jun 2021 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2021 - 18 Apr 2024Source: FactSet Research Systems Inc.
